Clinical trials: Headache Disorder
Migraine
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound.
- Trial name
- Ubro Peds (NCT05125302)
- Testing
- Ubrogepant
- Where
- 129 sites in United States, Puerto Rico
- Volunteers
- 1,059 people
- Sponsor
- AbbVie
Migraine
A Randomized, Double-blind Clinical Investigation to Evaluate the Use of the Relievion™ Device in Treating Migraine.
This study will evaluate the clinical performance and safety of a self-administered abortive treatment for migraine headache using combined occipital and supraorbital transcutaneous nerve stimulator (Neurolief device, Relievion™).
- Trial name
- NCT03185559
- Testing
- Relievion Device- Treatment Stimulation
- Where
- Israel
- Volunteers
- 8 people
- Sponsor
- Neurolief Ltd.
Migraine
Study on the Pharmacokinetics (PK) of DFN-15 vs Comparator and Food-effect on DFN-15 PK in Healthy Adult Subjects
An Open-Label, Three-Way Randomized, Single Dose Crossover Study Comparing Bioavailability of DFN-15 under fasting conditions versus Comparator under fed conditions and to determine food-effect of DFN-15 in Healthy Adult Subjects
- Trial name
- NCT03282838
- Testing
- DFN-15 (fasted), DFN-15 (fed), Comparator Celebrex® (fed)
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Migraine With Aura
PArtial REbreathing for Migraine With Aura 1
A prospective, multi-centre, randomized, double-blind, sham-controlled, parallel-group, group-sequential study to investigate safety and effectiveness of the Rehaler partial rebreathing device, in adults suffering from migraine…
- Trial name
- PAREMA1 (NCT05546385)
- Testing
- Partial Rebreathing Device
- Where
- 15 sites in United States, Germany
- Volunteers
- 142 people
- Sponsor
- Rehaler
Migraine, Major Depressive Disorder
A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder
The primary objective is to evaluate the efficacy of monthly 225 mg sc fremanezumab in adult participants with migraine and major depressive disorder (MDD) The secondary objectives are to evaluate the efficacy of monthly 225 mg…
- Trial name
- NCT04041284
- Testing
- Fremanezumab
- Where
- 64 sites in United States, Czechia and 11 more
- Volunteers
- 353 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Migraine Disorders
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine
Chronic Migraine (CM), or 15 or more migraine headaches per month, is common in tertiary headache care and is associated with a number of deleterious outcomes, especially higher disability and poorer quality of life, relative to…
- Trial name
- NCT01435941
- Testing
- Non-steroidal anti-inflammatory drug (NSAID), Triptan
- Volunteers
- 11,249 people
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Headache
An Open-label Study to Evaluate Topiramate Therapy in Migraine Patients, and Its Effects on Subject Responsiveness to Migraine Treatment With Triptans
The purpose of this study is to evaluate whether prophylactic use of topiramate (preventative use before a migraine attack) enhances the effectiveness of migraine treatment with triptans.
- Trial name
- NCT00261469
- Testing
- topiramate
- Volunteers
- 38 people
- Sponsor
- Janssen-Ortho Inc., Canada
Migraine
Machine Learning Assessment of Next-Day Migraine Likelihood
Development of a machine learning (ML) algorithm for assessment of next-day migraine likelihood, drawing on self-reported migraine-related information, and geographic location, collected via the Nerivio app- a mobile application…
- Trial name
- NCT07227194
- Where
- United States
- Volunteers
- 53,065 people
- Sponsor
- Theranica
Migraine
STOP PAIN: Septal Closure of PFO - Does it Prevent Migraine?
The primary objective of this Study is to compare the effect of transcatheter device closure of atrial shunting to a non-closure control group over a period from cessation of procedure related medication at 3 months until 9…
- Trial name
- NCT00369499
- Testing
- PFO Closure
- Where
- Germany
- Volunteers
- 656 people
- Sponsor
- Abbott Medical Devices
Migraine
Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
This study is the first study in humans with CVT-427 (zolmitriptan inhalation powder) and is designed to evaluate the safety, tolerability, and PK of single ascending doses of CVT-427 in adult healthy volunteers.
- Trial name
- NCT02609945
- Testing
- zolmitriptan, CVT-427 (zolmitriptan inhalation powder),
- Where
- 2 sites in United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Acorda Therapeutics
Migraine Disorders
A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period
The purpose of this study is to test the effect on blood pressure of sumatriptan and naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only naproxen sodium when these drugs are taken…
- Trial name
- NCT00792636
- Testing
- sumatriptan and naproxen sodium combination tablet, sumatriptan tablet, naproxen sodium tablet
- Where
- 49 sites in United States
- Volunteers
- 407 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders, Refractory Migraine
EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization
This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal…
- Conditions
- Migraine Disorders, Refractory Migraine, Chronic Migraine
- Trial name
- EMBRACE (NCT07313800)
- Testing
- TEMMA Endovascular Treatment
- Where
- United States
- Sponsor
- Cortex Neurovascular
Migraine
The Effectiveness and Safety of Topiramate on Prevention of Chronic Migraine
The purpose of this study is to evaluate the safety and effectiveness of individualized doses (50 to 200 milligrams) of topiramate tablets compared against placebo for the prevention of chronic migraine headaches over a period of…
- Trial name
- NCT00216606
- Testing
- topiramate
- Volunteers
- 59 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Migraine
A Study of the Safety, Tolerability, Pharmacokinetics, And Effects On Histamine-Induced Wheal Of PF-05180999 In Healthy Adults
PF-05180999 is a phosphodiesterase-2 inhibitor that is hypothesized to be able to reduce vascular permeability. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and effects on histamine-induced…
- Trial name
- NCT01981499
- Testing
- PF-05180999, 120 mg MR PF-05180999, 360 mg MR PF-05180999
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Pfizer
Migraine
Maximizing Outcomes in Treating Acute Migraine
AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults.
- Trial name
- MOMENTUM (NCT03896009)
- Testing
- AXS-07 (MoSEIC meloxicam and rizatriptan), Meloxicam, Rizatriptan
- Where
- 85 sites in United States
- Volunteers
- 1,594 people
- Sponsor
- Axsome Therapeutics, Inc.
Migraine Disorders, Headache
Safety and Efficacy of Botulinum Toxin Type A (BOTOX®) to Treat Chronic Migraine in Korea
This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of botulinum toxin Type A to treat Chronic Migraine in clinical practice.
- Trial name
- NCT01976611
- Testing
- botulinum toxin Type A
- Where
- South Korea
- Volunteers
- 402 people
- Sponsor
- Allergan
Migraine
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)
The purpose of this study is to test the effectiveness of a marketed drug in the treatment of a menstrual migraine attack.
- Trial name
- NCT00111709
- Testing
- MK0462, rizatriptan benzoate / Duration of Treatment -1 day
- Volunteers
- 393 people
- Sponsor
- Organon and Co
Migraine, Headache
Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
The purpose of this study is to determine whether Topiramate is effective in preventing the development of chronic daily headache among patients with episodic migraine headaches.
- Conditions
- Migraine, Headache, Classic Migraine, Common Migraine
- Trial name
- NCT00212810
- Testing
- Topiramate
- Volunteers
- 385 people
- Sponsor
- Ortho-McNeil Neurologics, Inc.
Medication Overuse Headache
Pilot Study of DFN-11 Injection in Medication Overuse Headache
Efficacy and Safety Pilot Study of DFN-11 Injection in Medication Overuse Headache
- Trial name
- NCT02583425
- Testing
- DFN-11 Injection
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Dr. Reddy's Laboratories Limited